Identification of miR-29c-3p as a Robust Normalizer for Urine microRNA Studies in Bladder Cancer.

RT-qPCR bladder cancer miRNA normalizer reference miRNA urine

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
22 Oct 2020
Historique:
received: 17 09 2020
revised: 09 10 2020
accepted: 19 10 2020
entrez: 27 10 2020
pubmed: 28 10 2020
medline: 28 10 2020
Statut: epublish

Résumé

Bladder cancer (BC) is among the most frequent malignancies worldwide, being the most expensive cancer to treat and monitor and the most lethal urological cancer. Urine microRNAs (miRNAs) have been proposed as novel non-invasive biomarkers to early diagnose and monitor BC patients in order to avoid the performance of current aggressive diagnostic techniques. However, huge discrepancies arise among studies mainly due to the lack of standardization in the normalization, a crucial step in all miRNA studies. Our aim was to identify the best miRNA normalizer for miRNA studies in urine of BC patients. We evaluated the performance of 110 candidate miRNAs in urine of 35 BC patients and 15 healthy controls by Real Time quantitative Polymerase Chain Reaction (RT-qPCR) followed by a stability analysis with RefFinder. In this screening stage, miR-29c-3p arose as the most stably expressed miRNA in BC and controls, with a good expression level. Stability of miR-29c-3p expression was validated in an independent cohort of 153 BC patients and 57 controls. Finally, we evaluated the robustness of miR-29c-3p as normalizer in the expression study of miR-200c-3p, a potential diagnostic marker for BC. We propose miR-29c-3p as a normalizer for miRNA studies in BC urine. This is the first study that characterizes a reliable normalizer that may allow the comparison of future urine miRNA studies as non-invasive biomarkers for BC diagnosis and monitoring.

Identifiants

pubmed: 33105660
pii: biomedicines8110447
doi: 10.3390/biomedicines8110447
pmc: PMC7690381
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI17/00495
Organisme : Generalitat Valenciana
ID : ACIF/2017/138
Organisme : Sociedad Española de Trombosis y Hemostasia
ID : .
Organisme : Sociedad Española de Angiología y Cirugía Vascular
ID : .

Références

Urol Oncol. 2018 Dec;36(12):531.e1-531.e8
pubmed: 30322728
Med Sci (Basel). 2018 Dec 07;6(4):
pubmed: 30544619
Sci Rep. 2015 May 27;5:10437
pubmed: 26014226
PLoS One. 2019 Mar 13;14(3):e0213622
pubmed: 30865706
Sci Rep. 2018 Jul 18;8(1):10875
pubmed: 30022109
PLoS One. 2017 Oct 27;12(10):e0187005
pubmed: 29077772
Med J Islam Repub Iran. 2016 Dec 29;30:475
pubmed: 28491850
BMC Res Notes. 2014 Oct 10;7:715
pubmed: 25304816
Mol Cancer. 2015 Nov 14;14:194
pubmed: 26576778
J Mol Diagn. 2013 Sep;15(5):695-705
pubmed: 23945108
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2018 Apr 17;9(29):20658-20669
pubmed: 29755679
BMC Mol Biol. 2006 Oct 06;7:33
pubmed: 17026756
Curr Med Chem. 2012;19(22):3653-63
pubmed: 22680923
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Clin Chem. 2015 Nov;61(11):1333-42
pubmed: 26408530
Sci Rep. 2019 Dec 23;9(1):19677
pubmed: 31873160
J Mol Diagn. 2016 Jan;18(1):15-22
pubmed: 26586227
Genome Biol. 2009;10(6):R64
pubmed: 19531210
Transl Androl Urol. 2019 Feb;8(1):5-11
pubmed: 30976562
Sci Rep. 2017 Jul 17;7(1):5619
pubmed: 28717125
Urol Oncol. 2010 Nov-Dec;28(6):655-61
pubmed: 19375957
J Mol Diagn. 2008 Sep;10(5):411-4
pubmed: 18687791
PLoS One. 2014 Jul 11;9(7):e100793
pubmed: 25014919
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
Sci Rep. 2017 Jan 04;7:39782
pubmed: 28051134
Clin Genitourin Cancer. 2016 Oct;14(5):e493-e499
pubmed: 27157639
Plant Mol Biol. 2012 Jan 31;:
pubmed: 22290409
J Cancer. 2019 Jul 8;10(17):4038-4044
pubmed: 31417648
Int J Mol Sci. 2018 Sep 20;19(10):
pubmed: 30241379
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Biomed Sci. 2012 Oct 17;19:90
pubmed: 23075324
Mol Biotechnol. 2016 Mar;58(3):179-87
pubmed: 26798072
J Mol Diagn. 2014 Jan;16(1):106-15
pubmed: 24211363
Br J Cancer. 2012 Jun 26;107(1):123-8
pubmed: 22644299
Exp Mol Med. 2010 Nov 30;42(11):749-58
pubmed: 20890088
Biotechnol Lett. 2004 Mar;26(6):509-15
pubmed: 15127793
Dis Markers. 2015;2015:973597
pubmed: 26078486
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Int J Cancer. 2013 Dec 1;133(11):2631-41
pubmed: 23686449
J Transl Med. 2014 Nov 04;12:305
pubmed: 25367080
J Biomed Sci. 2015 Jan 23;22:9
pubmed: 25614041
PLoS One. 2017 Aug 31;12(8):e0183435
pubmed: 28859135
Oncotarget. 2016 Dec 27;7(52):86290-86299
pubmed: 27863434

Auteurs

Julia Oto (J)

Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, 46026 Valencia, Spain.

Emma Plana (E)

Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, 46026 Valencia, Spain.
Angiology and Vascular Surgery Service, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.

Álvaro Fernández-Pardo (Á)

Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, 46026 Valencia, Spain.

Fernando Cana (F)

Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, 46026 Valencia, Spain.

Manuel Martínez-Sarmiento (M)

Department of Urology, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.

César D Vera-Donoso (CD)

Department of Urology, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.

Francisco España (F)

Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, 46026 Valencia, Spain.

Pilar Medina (P)

Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, 46026 Valencia, Spain.

Classifications MeSH